Contrast agent developer Molecular Biosystems has announced that its Japanese partner Chugai Pharmaceutical Co. is set to begin clinical trials in Japan for radiology applications of its FS069 ultrasound contrast agent (known outside of Japan as Optison). In December, Chugai of Tokyo began trials of the agent for use in the assessment of left ventricular opacification and myocardial perfusion. For initiating the latest trials, Chugai has paid San Diego-based MBI $2 million.
By AuntMinnie.com staff writersMarch 28, 2000
Copyright © 2000 AuntMinnie.com